Business Wire

ENDEAVOUR-VISION

22.4.2021 08:32:07 CEST | Business Wire | Press release

Share
Endeavour Vision closes Endeavour Medtech Growth II LP at USD 375m to invest in transformative healthcare technologies

Endeavour Vision today announces the closing of Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies - 21 of which have exited via an acquisition or IPO.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005851/en/

The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions. Therefore, healthcare innovation is set to remain a long-term priority that is expected to generate attractive growth and a diverse set of opportunities for investors. The fund has already supported seven companies with investments totalling more than USD 100 million: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.

“Governments, citizens and investors are now more aware than ever of our healthcare systems’ strategic importance and current limitations,” said Bernard Vogel, Co-Founder and Managing Partner, Endeavour Vision. “This is accelerating the demand for pioneering solutions that can deliver sustainable healthcare. As such, EMG II LP’s timing could not be better. We want to thank the fund’s investors for their confidence in our team and strategy. In backing the bright future of this fast-growing, dynamic industry, our investors will also benefit from seeing the direct impact of their investments on people’s lives.”

“As a responsible investor working on behalf of UK Local Government Pension Schemes, we focus on seeking sustainable, long-term, risk-adjusted value to the pension scheme members through opportunities that provide a positive contribution to society,” said Nicholas Hinchliffe, Investment Director, Private Equity Investments, Local Pensions Partnership Investments. “Healthcare and health technology offers such an investment profile and helps diversify our client portfolios, and by investing in this vibrant sector through Endeavour Vision’s EMG II LP, we are able to access developments in ground-breaking clinical treatments.”

Endeavour Vision is one of the largest international investment teams focused on medtech and digital health. The firm partners with game-changing companies, actively supporting them beyond capital, with strategic and operational expertise to enable their global success.

“Medical technology and digital health are truly unique within the healthcare sector because they offer the opportunity to invest in companies in the early stages of commercialisation and before major value-inflection milestones, yet still at attractive valuations.” says Damien Tappy, President and Managing Partner, Endeavour Vision. “As recognised industry experts on both sides of the Atlantic, we are excited about the massive accelerated transformation of healthcare delivery over the next decade and the leading role Endeavour Vision can play in this.”

For more information about Endeavour Vision, please see our infographic . Two summaries are also available about EMG II LP fund and its current portfolio companies .

- Ends -

About Endeavour Vision

Endeavour Vision is a venture capital and growth equity firm founded in 2000, that invests in growth-stage medtech and digital health companies in Europe and the US. Its international investment teams are based in two global healthcare hubs in Geneva, Switzerland, and Minneapolis, US. For more information and a full list of portfolio companies, visit endeavourvision.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release

EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu

NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release

Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,

TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release

Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac

Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release

HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of

Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release

Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye